WilmerHale Advises Underwriters in the $692.3 Million Public Offering of Kymera Therapeutics

WilmerHale Advises Underwriters in the $692.3 Million Public Offering of Kymera Therapeutics

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale advised the underwriters in the public offering of 8,050,000 shares of common stock of Kymera Therapeutics, Inc. (NASDAQ: KYMR), reflecting the full exercise of the underwriters’ option to purchase an additional 1,050,000 shares. Kymera is a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD). Kymera received approximately $692.3 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related expenses. 

The WilmerHale team was led by Lisa Firenze and Andrew Langworthy and included Kevin Cheng, Whitley Horning and Amy O’Connell, with assistance from Barish Ozdamar on intellectual property matters and Bruce Manheim on regulatory matters.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel